2022 ended on a high note but soft 2023 guidance maintained
-"Q4 22 sales exceeded expectations and both segments contributed healthily, with CA being the dominant growth engine. FPA however was somewhat restrained by external factors. While the 2022 margin is ..."
You may also be interested by these reports :
Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In ...
Appreciating aprocitentan – How the royalty deal might look like – TP raised to CHF 18.20 (from 15.90) / Add reiterated
Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and ...
We have integrated the first set of the 2022 figures. The significantly higher EPS stems mainly from the cancellation of the anticipated CHF-900m ...